Introduction
It has been suggested that aldehyde dehydogenase 1 (ALDH1) in breast cancer might play an opposing role depending on the type of cells, in which it is expressed (1, 2) . The presence of ALDH1 in tumor cells of breast cancer and other solid tumors was reported to define a population of 'so called' cancer stem cells (CSC) or tumor progenitor cells (3) . Such cells are believed to initiate and drive tumor progression and represent a subpopulation of cells particularly resistant to applied therapies (4) . Accordingly, tumor cell ALDH1 staining is associated with a more aggressive disease course in solid tumors (5) . On the contrary, the presence of ALDH1 in tumorassociated stroma correlates to patients' better outcome in breast carcinomas (1, 2) , although the mechanism of this phenomenon remains largely unknown. ALDH1 is also known to be active in the late steps of retinoic acid synthesis (6), a well-known inducer of epithelial cell differentiation and an inhibitor of proliferation and migration (7, 8, 9) . Its involvement in retinoic acid metabolism was demonstrated to mediate differentiation of normal human mammary epithelium (10) . Hypothetically, the role of ALDH1 in this process might be cell-specific and stromal cells expressing ALDH1 might modulate tumor development via production of retinoic acid (2) . This phenomenon highlights the importance of the interactions between tumor cells and their microenvironment.
Most frequently investigated in breast cancer (11) , ALDH1 has been detected also in tumor cells of prostate cancer (PCa) (12) where it was shown to be associated with worse clinical outcome (13, 14) . ALDH1-positive cells were shown to be potential tumor-initiating and metastasis-initiating cells in human PCa (15) . Additionally, ALDH1-expressing cells might contribute to tumor resistance to radiotherapy (16) . To the best of our knowledge, stromal ALDH1 staining has never been reported in PCa.
Therefore, in the current study, ALDH1 was investigated as a protein of potential dual clinical and biological relevance in PCa. ALDH1 expression was assessed in PCa cells as well as intratumoral stromal cells in primary PCa and unmatched PCa metastases. The results were compared to clinico-pathological data as well as patients' outcome. Moreover, in order to test impact of the presence of cell-specific ALDH1 on tumor cell differentiation and aggressiveness, the results were analysed in relation to different cytokeratins (CK5/6, CK14, CK8/18, CK19), a proliferation marker (Ki-67), EpCAM, and epithelial mesenchymal transition-related markers (E-cadherin, N-cadherin, vimentin) in primary PCa.
Material and methods

Patients
Three-hundred-ninety-eight patients with sporadic PCa were included in this study In addition, 98 hormone naive PCa patients from the Prostate Centre University Clinic Muenster (Germany) were selected for examination of their metastases to lymph nodes.
Moreover, visceral and bone metastases were obtained from 21 PCa patients who died of metastatic castration resistant PCa (CRPC) and who signed written informed consent for a rapid autopsy performed within 6 hours of death, under the aegis of the Prostate Cancer Donor Program at the University of Washington and approved by the Institutional Review Board of the University of Washington. The study was conducted according to REMARK study recommendations (19) .
TMA
Two tissue microarrays (TMAs) with primary PCa samples were prepared as described (17). Briefly, each TMA comprised of 0.6 mm-diameter tissue cores obtained from formalin-fixed paraffin embedded PCa specimens. Fragments of normal prostate and kidney tissues were introduced to TMAs as internal controls. All patients were represented by duplex tumor samples (in case of multifocal disease originated from two different tumor foci).
One-hundred-ninety-six samples of LNM from 98 hormone naive PCa patients were used to construct the LNM tissue microarray (TMA). Within the LNM TMA each patient was represented by duplicate cores.
Eighty-four CRPC metastases from 21 rapid autopsy patients (up to 4 sites per patient) were fixed in buffered formalin (bone metastases were decalcified in 10% formic acid) and embedded in paraffin and were used to construct the CRPC TMA using duplicate 1 mm diameter cores from these tissues.
All TMA sections were cut 4-µm-thick and placed on charged polylysine-coated slides (Superfrost Plus, BDH, Germany) for further examination.
Immunohistochemistry and its evaluation
ALDH1 staining and its evaluation was performed as described (2) . Briefly, mouse monoclonal anti-ALDH1 antibody (44/ALDH1, BD Biosciences, US) diluted 1:500 was incubated overnight at 4°C and envisioned by DAKO ChemMate Detection Kit Peroxidase/DAB, Rabbit/Mouse (Dako, Denmark) to detect ALDH1 protein in PCa.
For ALDH1 staining in tumor cells, intensity of the staining (negative, weak, moderate or strong) was multiplied by percentage of the stained tumor cells to result in index score of 0 to 300. The mean value of all index scores was used as a cut-off to determine negative (index score lower than mean) or positive expression (index score equal or greater than mean). ALDH1 expression in stromal cells was determined as no expression, moderate or strong expression in less than 10%, in 10-9 50% and more than 50% of stromal cells. The results were classified as negative or positive stromal staining according to the cut-off equal 10% to positive cells.
Immunohistochemistry for CK5/6, CK14, CK8-18, CK19, E-cadherin, N-cadherin, vimentin, EpCAM and Ki-67 were performed as described (18) .
Statistics
Statistical analysis was performed using SPSS software licensed for Medical University of Gdańsk. Chi-square, and Fisher's exact tests, as well as Pearson twotailed correlation test and independent samples t-test were used in order to compare the results to molecular factors and clinico-pathological parameters. Associations between protein expression profiles and time to biochemical recurrence and metastasis-free survival were evaluated using Log Rank (Mantel Cox) test and Kaplan-Meier plot. To estimate hazard risk, Cox-Hazard-Potential regression analysis (CI 95%) was done. All results were considered statistically significant if p<0.05 and highly statistically significant if p<0.001.
Results
ALDH1 expression in tumor and stromal cells of primary prostate cancers
Five-hundred-fifty-one tumor samples from 348 PCa patients were informative for ALDH1 staining in tumor and stromal cells. Meier log rank analysis, p=0.010) and showed a trend towards shorter time to metastasis (Kaplan-Meier log rank analysis, p=0.051) (Fig. 2) .
Positive ALDH1 staining in stromal cells correlated to less aggressive histopathological characteristics of a primary tumor such as lower T (Chi 2 =6.969, p=0.008) and negative N status (Chi 2 =5.717, p=0.017), higher Gleason score (Chi 2 =17.001, p<0.001) as well as less frequently occurring BR (Chi 2 =5.023, p=0.025) (Tab. 1).
Stromal ALDH1 was also associated with patients' longer time to BR (Kaplan-Meier log rank analysis, p=0.017) and longer time to metastasis (Kaplan-Meier log rank analysis, p=0.050) ( Within bone metastases, 38.1% of patients were negative for ALDH1 both in tumor cells and stroma. ALDH1 staining in exclusively tumor cells was found in 38.1% of patients, only in stroma -9.5%, whereas in both tumor and stromal cells -in 14.3% of cases. In metastases to other organs (liver, lung and kidney), 27.8% patients were positive for ALDH1 in tumor and stromal cells, and 11.15% were negative for ALDH1 in both compartments. Interestingly, none of the patients were positive for ALDH1 staining detected exclusively in stromal cells of these metastases, whereas 72.2%
were positive for ALDH1 detected only in tumor cells. To the best of our knowledge, the current study is the first one evaluating ALDH1 expression in both tumor and stromal cells in PCa metastases to lymph nodes and distant organs. 
Molecular characterization of primary prostate cancers in context of
Conclusions
The presented data support the hypothesis that ALDH1 might play an opposing role in tumor cells and tumor-associated stromal cells in PCa (Fig. 3) . We hypothesize that ALDH1-positive stromal cells can induce differentiation and attenuate PCa progression, whereas ALDH1 expressed in tumor cells indicates a more aggressive phenotype and worse clinical outcome. This observation is similar to previous reports in breast cancer patients (1, 2) . Therefore, we hypothesize the presence of ALDH1(+) stromal cells might also attenuate the growth and progression of other epithelial malignancies. Tables   Table 1 Clinical 
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